Pamiparib

Overview

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).

Background

Indication

用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS	2024/11/18	NCT06692491	Phase 2	Not yet recruiting	Peking University Shenzhen Hospital
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)	2024/04/26	NCT06387056	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer	2022/12/15	NCT05652283	Phase 2	Active, not recruiting	Bai-Rong Xia
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer	2022/09/02	NCT05526924	Phase 1	Recruiting	University of Chicago
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer	2022/08/10	NCT05494580	Phase 1	Recruiting	Sun Yat-sen University
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure	2022/08/05	NCT05489926	Phase 2	Active, not recruiting	Zhejiang Cancer Hospital
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy	2022/08/02	NCT05483543	Phase 2	Recruiting	Fudan University
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer	2022/05/17	NCT05376722	Phase 2	Recruiting	Hongqian Guo
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation	2022/04/14	NCT05327621	Phase 2	Recruiting	Sun Yat-sen University
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer	2021/09/16	NCT05044871	Phase 2	Completed	Tongji Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Pamiparib Capsules	百济神州（苏州）生物科技有限公司	国药准字H20210016	化学药品	胶囊剂	4/30/2021

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access